-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly Announced Topline Phase 3 Results From ACHIEVE-1, Evaluating The Safety And Efficacy Of Orforglipron Compared To Placebo In Adults With Type 2 Diabetes And Inadequate Glycemic Control With Diet And Exercise Alone

Benzinga·04/17/2025 10:48:14
Listen to the news
  • Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses
  • The investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary endpoint
  • The overall safety and tolerability profile of orforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies